Abstract
Prolyl hydroxylase inhibitors (PHIs) are oral agents that might increase availability of anemia treatment options for patients with chronic kidney disease (CKD). The 36-Item Short Form (SF-36) Vitality score is a patient-reported measure of energy/fatigue – common and important outcomes in patients with CKD. Direct comparative evidence on health-related quality of life from randomized controlled trials (RCTs) between PHIs has not been identified. We conducted an indirect treatment comparison (ITC) of changes in SF-36 Vitality score observed in placebo-controlled RCTs of daprodustat and roxadustat.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
